Responsive neurostimulation (RNS) for the treatment of epilepsy involves the use of one (1) or more implantable electric leads that serve as both a seizure detection and neurostimulation function. The device is programmed using a proprietary algorithm to recognize seizure patterns from electrocorticography output and to deliver electrical stimulation with the goal of terminating a seizure. One device, the Neuropace RNS System, has U.S. Food and Drug Administration (FDA) approval for the treatment of refractory partial epilepsy.
RNS may be considered medically necessary for individuals with partial epilepsy who meet ALL of the following criteria:
RNS is considered experimental investigational and therefore non covered for all other indications. Scientific evidence does not support the use of RNS for any other indications.